What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?
Author:
- 1 September 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 19 (5) , 420-424
Abstract
This article examines the potential mechanisms underlying adverse risk observed in four randomized controlled trials of anemia correction in chronic kidney disease (CKD) patients. The Normal Hematocrit Study, Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin-beta, Correction of Hemoglobin and Outcomes in Renal Insufficiency, and Trial to Reduce Cardiovascular Events with Aranesp Therapy demonstrate increased risk of mortality and/or cardiovascular complications with targeting of a higher hemoglobin (Hb) in CKD patients. Although a higher Hb level was targeted in these trials, erythropoiesis-stimulating agent (ESA) exposure itself might account for the observed increased risk. This is because, in these trials, achieving a normal or near normal Hb was associated with improved survival and reduced cardiovascular risk. Indeed, it was the 'targeting' of a higher Hb with ESA that seemed to be the problem. Observational data, although conflicting, on the whole provide support for high dosage of ESA being harmful but cannot, by their very nature, prove causality. After 20 years of ESA use, is it plausible that ESAs could be toxic? How does one reconcile conflicting observational data with a hypothesis that postulates ESA toxicity? Does the biology of erythropoietin provide a mechanistic explanation? The answers to these questions, among others, will be important in charting a future role for ESAs in treating CKD anemia.Keywords
This publication has 31 references indexed in Scilit:
- Relationship between Epoetin Alfa Dose and MortalityClinical Journal of the American Society of Nephrology, 2010
- Anemia Management and Association of Race With Mortality and Hospitalization in a Large Not-for-Profit Dialysis OrganizationAmerican Journal of Kidney Diseases, 2009
- Estimated Effect of Epoetin Dosage on Survival among Elderly Hemodialysis Patients in the United StatesClinical Journal of the American Society of Nephrology, 2009
- Effect of Epoetin Alfa Dose Changes on Hemoglobin and Mortality in Hemodialysis Patients with Hemoglobin Levels Persistently below 11 g/dLClinical Journal of the American Society of Nephrology, 2009
- Endothelial Activation Markers in Anemic Non-Dialysis Chronic Kidney Disease PatientsNephron Clinical Practice, 2008
- Erythropoietin, Iron Depletion, and Relative Thrombocytosis: A Possible Explanation for Hemoglobin-Survival Paradox in HemodialysisAmerican Journal of Kidney Diseases, 2008
- Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomesKidney International, 2008
- High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO)Thrombosis and Haemostasis, 2008
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activitiesProceedings of the National Academy of Sciences, 2006